Mitchell & Pahl Private Wealth LLC Has $909,000 Stock Position in AstraZeneca PLC (NASDAQ:AZN)

Mitchell & Pahl Private Wealth LLC lifted its position in shares of AstraZeneca PLC (NASDAQ:AZN) by 5.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 13,872 shares of the company’s stock after purchasing an additional 771 shares during the quarter. Mitchell & Pahl Private Wealth LLC’s holdings in AstraZeneca were worth $909,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also modified their holdings of the company. Martin Investment Management LLC boosted its stake in AstraZeneca by 2.8% during the third quarter. Martin Investment Management LLC now owns 284,204 shares of the company’s stock worth $22,571,000 after buying an additional 7,615 shares in the last quarter. Nordea Investment Management AB bought a new position in shares of AstraZeneca during the 4th quarter worth about $754,000. Integrated Advisors Network LLC boosted its position in shares of AstraZeneca by 46.6% during the 3rd quarter. Integrated Advisors Network LLC now owns 43,610 shares of the company’s stock valued at $3,398,000 after acquiring an additional 13,860 shares in the last quarter. Creative Planning increased its stake in AstraZeneca by 8.0% in the third quarter. Creative Planning now owns 224,751 shares of the company’s stock valued at $17,510,000 after acquiring an additional 16,692 shares during the period. Finally, Soros Fund Management LLC raised its position in AstraZeneca by 8.2% in the third quarter. Soros Fund Management LLC now owns 2,652,771 shares of the company’s stock worth $206,677,000 after purchasing an additional 201,233 shares in the last quarter. 20.35% of the stock is currently owned by institutional investors.

AstraZeneca Stock Down 0.5 %

Shares of AZN opened at $66.60 on Tuesday. The company has a market capitalization of $206.53 billion, a P/E ratio of 31.87, a PEG ratio of 1.04 and a beta of 0.46. AstraZeneca PLC has a one year low of $60.47 and a one year high of $87.68. The business’s 50 day simple moving average is $66.11 and its 200-day simple moving average is $74.46. The company has a debt-to-equity ratio of 0.71, a current ratio of 0.93 and a quick ratio of 0.71.

AstraZeneca (NASDAQ:AZN) last posted its quarterly earnings data on Tuesday, November 12th. The company reported $1.04 EPS for the quarter, topping analysts’ consensus estimates of $1.01 by $0.03. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The company had revenue of $13.57 billion for the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the previous year, the firm earned $0.87 earnings per share. The business’s revenue was up 18.0% on a year-over-year basis. As a group, sell-side analysts predict that AstraZeneca PLC will post 4.11 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have weighed in on AZN shares. Deutsche Bank Aktiengesellschaft raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. UBS Group upgraded AstraZeneca from a “sell” rating to a “neutral” rating in a research report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.